Browsing by Author "Kayikçioǧlu Ö.R."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma
    (Wichtig Editore s.r.l., 2004) Erkin E.F.; Tarhan S.; Kayikçioǧlu Ö.R.; Deveci H.; Güler C.; Göktan C.
    PURPOSE. To evaluate the effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma (POAG) by means of an observer-masked, prospective clinical study. METHODS. Thirty-two patients with newly diagnosed POAG were included in the study. The patients were randomized into two groups. The first group was treated with betaxolol 0.50% twice daily and the second group with latanoprost 0.005% once daily. Baseline and post-treatment examinations on the first and third months of treatment included intraocular pressure (IOP) measurement, automated visual field testing, and ocular blood flow assessment. For evaluation of visual fields, mean defect and pattern standard deviation indices were used. Ocular blood flow was assessed by means of color Doppler imaging of the central retinal artery (CRA) and the temporal short posterior ciliary artery (PCA). For each vessel, peak systolic (PSV) and end-diastolic (EDV) blood flow velocities were measured and resistivity index (RI) calculated. RESULTS. After exclusion of one noncompliant patient, the study was completed with 31 eyes of 31 patients. Both drugs significantly reduced IOP (p<0.05). The mean IOP lowering effect of latanoprost was significantly higher than that of betaxolol (p=0.03). Visual field indices exhibited no significant changes in either group (p>0.05). There were no significant changes in PSV or EDV measurements of CRA or PCA in either group (p>0.05). RI decreased in both CRA and PCA with both drugs. The mean changes between baseline and 3 month blood flow measurements were not significantly different between betaxolol and latanoprost (p>0.05). CONCLUSIONS. Over a treatment period of 3 months, both betaxolol and latanoprost tended to improve ocular blood flow without one of them being superior to the other. The results suggest that the direct (non IOP-dependent) influence on ocular circulation is better for betaxolol than for latanoprost. In addition, neither drug caused significant generalized improvements in visual fields during this period.
  • No Thumbnail Available
    Item
    The evaluation of scleral buckling and pars plana vitrectomy in the management of primary rhegmatogenous retinal detachment
    (Gazi Eye Foundation, 2016) Bilgin S.; Kayikçioǧlu Ö.R.
    Purpose: To evaluate the results of scleral buckling (SB) and pars plana vitrectomy (PPV) surgeries for the treatment of rhegmatogenous retinal detachment. Materials and Methods: This study included cases who received surgical treatment due to primary rhegmatogenous retinal detachment in our clinic, between March 2003 and April 2014. According to surgery techniques, the cases were evaluated retrospectively and divided into two groups as SB and PPV. The groups were evaluated for anatomical and functional success and complications. Results: Single-surgery anatomic success was achieved in 48 of 52 (94%) eyes that underwent PPV and in 42 of 52 (80%) eyes that underwent SB (p=0.085). The mean VA improvement in the PPV group was significantly better than in the SB group (PPV, 1.196 logMAR (11 standard ETDRS line); SB, 0.155 logMAR (1.5 standard ETRDS line)) (p<0.001). Subfoveal perfluorocarbon liquid retention was observed in two eyes in the PPV group. Conjunctival pyogenic granuloma occured in one eye in the SB group. Endophthalmitis was not observed in any patient in both groups . Conclusion: Although both surgical methods seems to be efficient treatment modalities for primary regmatogenous retinal detachment, better anatomical outcomes were achieved with PPV. In addition, complication types are different due to different surgical procedures and adjunctive tamponade, scleral buckling elements and perfluorocarbon use. © 2016 Gazi Eye Foundation. All rights reserved.